







Email: caroline.smith@nhsbt.nhs.uk Mobile: +44 (0) 771 144 7302

Issued by JPAC: 28 July 2021 Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 27 - 2021

Infertility

This change applies to ALL the Tissues and Cell Donor Selection Guidelines as stated below

Bone Marrow and Peripheral Blood Stem Cells DSGs

Please amend the following sections of this entry:

Obligatory:	 Must not donate if: a) Under investigation. b) Less than 12 weeks after completion of treatment with clomiphene (Clomid). c) Less than 12 weeks after completion of treatment with tamoxifen. d) Has ever been given human gonadotrophin of pituitary origin. e) Has received donated eggs or embryos since 1980. f e) If donor knows that they have ever been treated with Metrodin HP®.
Additional Information:	The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy. There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.
	Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.
Reason for Change:	To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.

\Continued









Email: caroline.smith@nhsbt.nhs.uk

Mobile: +44 (0) 771 144 7302

The entry has been updated in line with the SaBTO Microbiological Safety Guidelines which state that there is no evidence that donated human eggs can transmit CJD.

Cord Blood Donor Selection Guidelines

Please amend the following sections of this entry:

Obligatory:	Must not donate if: a) Has ever been given human gonadotrophin of pituitary origin.
	b) Has received donated eggs or embryos since 1980.
	e b) If donor knows that they have ever been treated with Metrodin HP®.
See if Relevant	Fertility Treatment Prion Associated Diseases
Additional Information:	The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.
	Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.
Reason for Change:	To add additional information to clarify when the use of human genadetrophin of pituitary origin (follicle stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK. The entry has been updated in line with the SaBTO Microbiological Safety Guidelines which state that there is no evidence that donated human eggs can transmit CJD.

Live and Deceased Tissue Donor DSGs

Please amend the following sections of this entry:

Obligatory:	Must not donate if: a) Has ever been given human gonadotrophin of pituitary origin.
	b) Has received donated eggs or embryos since 1980.
	e b) If donor knows that they have ever been treated with Metrodin HP®.

\Continued









Email: caroline.smith@nhsbt.nhs.uk

Mobile: +44 (0) 771 144 7302

Additional Information:

The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given.

There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.

Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.

Reason for Change:

To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK. The entry has been updated in line with the SaBTO Microbiological Safety Guidelines which state that there is no evidence that donated human eggs can transmit CJD.

Smaclena

Dr Sheila MacLennan

Professional Director - Joint UKBTS Professional Advisory Committee